The 15 top R&D spenders in the global biopharma business

July 14, 2016

In 2015, the top 15 R&D spenders in the global biopharma business spent a whopping $87 billion on research and development. Expectations are high for the Big Pharma and Big Biotech companies on this list. Recent years have seen a surge in drug approvals and the years to come could be even better. See who topped the charts:

1. Roche: $9.67B

2. J&J: $9B

3. Novartis: $8.9B

4. Pfizer: $7.7B

5. Merck: $6.7B

6. Bristol-Myers Squibb: $5.9B

7. AstraZeneca: $5.6B

8. Sanofi: $5.6B

9. Eli Lilly: $4.8B

10. GlaxoSmithKline: $4.38B

11. AbbVie: $4.28B

12. Amgen: $4.07B